Skip to main content
SpringerLink
Log in

Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

High blood pressure represents one of the leading risk factors for the development of stroke and its recurrence. This explains why blood pressure control is a major objective of antihypertensive treatment, both in primary and secondary prevention of this cerebrovascular disease. This paper reviews the evidence provided by randomized clinical trials on the favorable effects exerted by blood pressure reduction on this end point. Emphasis is given to the results of recently published clinical trials documenting that drugs acting on the renin-angiotensin system may exert cerebrovascular protective effects additive to the ones associated with blood pressure reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kearney PM, Whelton M, Reynolds K, et al.: Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217–223.

    PubMed  Google Scholar 

  2. Kjeldsen SE, Julius S, Hedner T, Hansson L: Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001, 10:190–192.

    Article  PubMed  CAS  Google Scholar 

  3. Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.

    Article  PubMed  Google Scholar 

  4. Lawes CM, Bennett DA, Feigin VL, Rodgers A: Blood pressure and stroke: an overview of published reviews. Stroke 2004, 35:776–785.

    Article  PubMed  Google Scholar 

  5. Kannel WB, Wolf PA, Verter J, McNamara PM: Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. JAMA 1970, 214:301–310.

    Article  PubMed  CAS  Google Scholar 

  6. MacMahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335:765–774.

    Article  PubMed  CAS  Google Scholar 

  7. Kannel WB, Wolf PA, McGee DL, et al.: Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA 1981, 245:1225–1229.

    Article  PubMed  CAS  Google Scholar 

  8. Domanski MJ, Davis BR, Pfeffer MA, et al.: Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999, 34:375–380.

    PubMed  CAS  Google Scholar 

  9. Truelsen T, Prescott E, Gronback M, et al.: Trends in stroke incidence. The Copenhagen city heart study. Stroke 1997, 28:1903–1907.

    PubMed  CAS  Google Scholar 

  10. Madhavan S, Ooi WL, Cohen H, Alderman MH: Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994, 23:395–401.

    PubMed  CAS  Google Scholar 

  11. Benetos A, Rudnichi A, Safar M, Guize L: Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 1998, 32:560–564.

    PubMed  CAS  Google Scholar 

  12. Nielsen WB, Lindenstrom E, Vestbo J, Jensen GB: Is diastolic hypertension an independent risk factor for stroke in the presence of normal systolic blood pressure in the middle-aged and elderly? Am J Hypertens 1997, 10:634–639.

    Article  PubMed  CAS  Google Scholar 

  13. Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213–1225.

    Article  PubMed  CAS  Google Scholar 

  14. Straus SE, Majumdar SR, McAlister FA: New evidence for stroke prevention: scientific review. JAMA 2002, 288:1388–1395.

    Article  PubMed  Google Scholar 

  15. Chalmers J, Todd A, Chapman N, et al.: International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. J Hypertens 2003, 21:651–663.

    Article  PubMed  Google Scholar 

  16. Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305–1315.

    Article  PubMed  CAS  Google Scholar 

  17. Gueyffier F, Boissel JP, Boutitie F, et al.: Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (Individual Data Analysis of Antihypertensive Intervention Trials) project collaborators. Stroke 1997, 28:2557–2562.

    PubMed  CAS  Google Scholar 

  18. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT study group. Lancet 1998, 351:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  19. Bilous R: Blood pressure control in type 2 diabetes: what does the United Kingdom prospective diabetes study (UKPDS) tell us? Nephrol Dial Transplant 1999, 14:2562–2564.

    Article  PubMed  CAS  Google Scholar 

  20. Hebert PR, Moser M, Mayer J, et al.: Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993, 153:578–581.

    Article  PubMed  CAS  Google Scholar 

  21. Gueyffier F, Bulpitt C, Boissel JP, et al.: Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA group. Lancet 1999, 353:793–796.

    Article  PubMed  CAS  Google Scholar 

  22. Wright JM, Lee CH, Chambers GK: Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug? CMAJ 1999, 161:25–32.

    PubMed  CAS  Google Scholar 

  23. Psaty BM, Smith NL, Siscovick DS, et al.: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997, 277:739–745.

    Article  PubMed  CAS  Google Scholar 

  24. Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000, 356:1955–1964.

    Article  PubMed  CAS  Google Scholar 

  25. McAlister FA, Sackett DL: Active-control equivalence trials and antihypertensive agents. Am J Med 2001, 111:553–558.

    Article  PubMed  CAS  Google Scholar 

  26. Mancia G, Grassi G: Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002, 20:1461–1464.

    Article  PubMed  CAS  Google Scholar 

  27. Klungel OH, Stricker BH, Paes AH, et al.: Excess stroke among hypertensive men and women attributable to under-treatment of hypertension. Stroke 1999, 30:1312–1318.

    PubMed  CAS  Google Scholar 

  28. Andersson OK, Almgren T, Persson B, et al.: Survival in treated hypertension: follow up study after two decades. BMJ 1998, 317:167–171.

    PubMed  CAS  Google Scholar 

  29. Benetos A, Thomas F, Bean KE, Guize L: Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003, 21:1635–1640.

    Article  PubMed  CAS  Google Scholar 

  30. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616.

    Article  PubMed  CAS  Google Scholar 

  31. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The antihypertensive and lipid-lowering treatment to prevent heart attack trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.

    Article  Google Scholar 

  32. Lithell H, Hansson L, Skoog I, et al.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875–886.

    Article  PubMed  CAS  Google Scholar 

  33. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.

    Article  PubMed  CAS  Google Scholar 

  34. Mancia G, Grassi G: Secondary prevention of stroke: old and new evidence. Aging Clin Exp Res 2002, 14:216–220.

    PubMed  Google Scholar 

  35. Adams HP Jr: Stroke: a vascular pathology with inadequate management. J Hypertens 2003, 21(Suppl 5):S3–S7.

    CAS  Google Scholar 

  36. MacMahon S: Blood pressure and the prevention of stroke. J Hypertens 1996, 14(Suppl 6):S39–S46.

    CAS  Google Scholar 

  37. PATS Collaborating Group: Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 1995, 108:710–717.

    Google Scholar 

  38. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033–1041.

    Article  Google Scholar 

  39. Schrader J, Luders S, Kulschewski A, et al.: Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005, 36:1218–1226.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinica Medica, Ospedale S. Gerardo, Università Milano Bicocca, Via Pergolesi 33, 20052, Monza (Milan), Italy

    Guido Grassi MD

Authors
  1. Guido Grassi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Arenare MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fosca Quarti Trevano MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raffaella Dell’Oro MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giuseppe Mancia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guido Grassi MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grassi, G., Arenare, F., Trevano, F.Q. et al. Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials. Current Science Inc 9, 299–304 (2007). https://doi.org/10.1007/s11906-007-0055-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-007-0055-x

Keywords

Search

Navigation